Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1157-1167

  Jannetto, Paul J ^a   Bratanow, Nancy C ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Midwest Comprehensive Pain Care   (United States)

Author keywords

Adverse drug reactions; Opioids; Pain management; Pharmacogenomics; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 2D6; DNA; HYDROCODONE; METHADONE; OPIATE; OXYCODONE; TRAMADOL;

ADULT; AFRICAN AMERICAN; AMERICAN INDIAN; ANALGESIA; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CHRONIC PAIN; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DNA EXTRACTION; DROWSINESS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG UTILIZATION; FEMALE; FIBROMYALGIA; GENE DUPLICATION; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HUMAN; HYPOTHESIS; INHERITANCE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIGRAINE; MYOFASCIAL PAIN; NAUSEA AND VOMITING; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SAFETY; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PAIN; PREVALENCE; RACE DIFFERENCE; SEQUENCE ANALYSIS; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DISEASE MANAGEMENT; DRUG MONITORING; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PAIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 70449503599     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.64     Document Type: Article

References (50)

1. Merskey H, Bogduk N: Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms (2nd Edition). IASP Press, WA, USA (1994).
2. Fox CD, Berger D, Fine PG: Pain Assessment and Treatment in the Managed Care Environment. A Position Statement from the American Pain Society. American Pain Society, IL, USA (2000).
3. Jacox AK, Carr DB, Chapman CR; US Department of Health and Human Services, Agency for Health Care Policy and Research: Acute Pain Management: Operative or Medical Procedures and Trauma Clinical Practice Guideline, Number 1. AHCPR Publication, MD, USA 92-10032 (1992).
4. Agency for Health Care Policy and Research; US Department of Health and Human Services: Management of Cancer Pain. Clinical Practice Guideline, Number 9. AHCPR Publication, MD, USA 94-0592 (1994).
5. Cancer pain relief and palliative care. Report of a WHO Expert Committee: World Health Organ. Tech. Rep. Ser. 804, 1-75 (1990).
6. Besson JM, Chaouch A: Peripheral and spinal mechanisms of nociception. Physiol. Rev. 67, 67-186 (1987).
7. Pappagallo M: Aggressive pharmacologic treatment of pain. Rheum. Dis. Clin. North Am. 25, 193-213, vii (1999).
8. Linder MW, Prough RA, Valdes RJ: Pharmacogenomics: a laboratory tool for optimization. Clin. Chem. 43, 254-266 (1997). ■ Concise overview of pharmacogenomics.
9. Fishbain DA, Fishbain D, Lewis J et al.: Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. Pain Medicine 5(1), 81-92 (2004). ■■ First to review clinical utility of pharmacogenetics for pain management. (Pubitemid 38404447)
10. Somogyi AA, Barratt DT, Coller JK: Pharmacogenetics of opioids. Clin. Pharm. Ther. 81(3), 429-444 (2007). ■■ Extensive review of pharmacogenetics for opioids.
11. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
12. Nebert DW, Dieter MZ: The evolution of drug metabolism. Pharmacology 61, 124-135 (2000).
13. Watson W, Litovitz TL, Klein-Schwartz W et al.: 2003 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 22(5), 335-404 (2004).
14. White S, Wong SHY: Standards of laboratory practice: analgesic drug monitoring. Clin. Chem. 44, 1110-1123 (1998). (Pubitemid 28213159)
15. Eriksson S, Berg LM, Wadelius M, Alderborn A: Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev. Technol. 1, 49-59 (2002).
16. Soderback E, Zackrisson AL, Lindblom B, Alderborn A: Determination of CYP2D6 gene copy number by pyrosequencing. Clin. Chem. 51, 522-531 (2005). (Pubitemid 40300227)
17. Schmidt N, Sittl R, Brune K, Geislinger G: Rapid determination of methadone in plasma, cerebrospinal fluid, and urine by gas chromatography and its application to routine drug monitoring. Pharm. Res. 10, 441-444 (1993). (Pubitemid 23080611)
18. Brosen K, Gram LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 36, 537-547 (1989). (Pubitemid 19175861)
19. Voora D, Erby C, Linder MW et al.: Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thrombosis Haemostasis 93(4), 700-705 (2005). (Pubitemid 40485406)
20. Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of antidepressant medication intolerance. Am. J. Psych. 160(10), 1830-1835 (2003).
21. Arranz MJ, Collier D, Kerwin RW: Pharmacogenetics for the individualization of pyschiatric treatment. Am. J. Pharmacogenomics 1(1), 3-10 (2001).
22. Dahl ML, Sjoqvist F: Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther. Drug Monit. 22, 114-117 (2000).
23. Sadee W: Pharmacogenomics. Br. Med. J. 319, 1-4 (1999).
24. Fagerlund TH, Braaten O: No pain relief from codeine? An introduction to pharmacogenomics. Acta Anaesthesiol. Scand. 45, 140-149 (2001).
25. Hardman JG, Limbird LE, Molinoff PB et al.: Goodman and Gilman's The Pharmacological Basis of Therapeutics (9th Edition). McGraw- Hill, NY, USA (1996).
26. Williams DG: Codeine phosphate in pediatric medicine. Br. J. Anaesth. 86, 329-331 (2001).
27. Way EL, Adler TK: The pharmacologic implications of the fate of morphine and its surrogates. Pharmacol. Rev. 12, 383-446 (1960).
28. Waife SO, Gruber CM Jr, Rodda BE, Nash JF: Problems and solutions to single-dose testing of analgesics: comparison of propoxyphene, codeine, and fenoprofen. Int. J. Clin. Pharmacol. Biopharm. 12, 301-304 (1975).
29. Poulsen L, Riishede L, Brosen K et al.: Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur. J. Clin. Pharmacol. 54, 451-454 (1998). (Pubitemid 28418810)
30. Buchert E, Woosley RL: Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics 2, 2-11 (1992).
31. Stamer UM, Lehnen K, Hothker F et al.: Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105, 231-238 (2003). (Pubitemid 37162492)
32. Uhl GR, Sora I, Wang Z: The μ opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc. Natl Acad. Sci. USA 96, 7752-7755 (1999).
33. Stamer UM, Stuber F: Genetic factors in pain and its treatment. Curr. Opin. Anaesthesiol. 20, 478-484 (2007).
34. Shi MM, Mehrens D, Dacus K: Pharmacogenomics: changing the health care paradigm. Modern Drug Discovery 4, 26-28, 30-32 (2001).
35. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-ana lysis of prospective studies. JAMA 279, 1200-1205 (1998).
36. Max MB, Payne R, Edwards WT: Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain (4th Edition). American Pain Society, IL, USA (1999).
37. McCaffery M, Portenoy RK: Overview of three groups of analgesics. In: Pain Clinical Manual (2nd Edition). McCaffery M, Pasero C (Eds). Mosby Inc., MO, USA 103-128 (1999).
38. Jannetto PJ, Wong SH, Gock SB et al.: Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping oxycodone cases for cytochrome P450 2D6. J. Anal. Toxicol. 26(7), 438-447 (2002).
39. Jin M, Gock SB, Jannetto PJ et al.: Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J. Anal. Toxicol. 29, 1-9 (2005).
40. Schulz M, Schmoldt A: Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58, 447-474 (2003). (Pubitemid 36869876)
41. American Pain Society, Quality of Care Committee: Quality improvement guidelines for the treatment of acute and cancer pain. JAMA 274(23), 1874-1880 (1995).
42. von Korff M, Dworkin SF, Le Resche L: Graded chronic pain status: an epidemiologic evaluation. Pain 40, 279-291 (1990).
43. Waddel G: Low back pain: a twentieth century health care enigma. Spine 21, 2820-2825 (1996).
44. Bernard S, Neville KA, Nguyen AT, Flockhart DA: Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 11, 126-135 (2007).
45. Berry PH, Katz JA, Chapman CR et al.: Pain: Current Understanding of Assessment, Management, and Treatments. National Pharmaceutical Council, VA, USA 101 (2001). www.scribd.com/doc/7563609/ Pain-Current-Understanding-of- Assessment-Management-and-Treatments
46. American Pain Society. Chronic pain in America: Roadblocks to relief www.ampainsoc.org/links/roadblocks (Accessed June 2007)
47. Joint Commission on Accreditation of Healthcare Organizations. Pain management standards. Effective January 1, 2001 www.jointcommission.org/ NewsRoom/health-care-issues.htm#9 (Accessed June 2007)
48. Haddox JD, Joranson D, Angarola RT et al.: The use of opioids for the treatment of chronic pain. American Academy of Pain Medicine, IL, USA, consensus statement. (1996). www.ampainsoc.org/advocacy/opioids.htm
49. FDA News. FDA Approves Updated Warfarin (Coumadin) Prescribing Information www.fda.gov/bbs/topics/NEWS/2007/ NEW01684.html (Accessed September 2007)
50. The NIH Guide: New Directions in Pain Research I. Government Printing Office, Washington, DC, USA (1998). http://grants.nih.gov/grants/guide/pa-files/ PA-98-102.html